Crispr Therapeutics Announced Preclinical Data From Its Investigational Programs For The Treatment Of Cardiovascular Disease, At The American Heart Association Scientific Sessions 2023
Portfolio Pulse from Benzinga Newsdesk
Crispr Therapeutics has announced preclinical data from its investigational programs for the treatment of cardiovascular disease. The data shows that CTX310 and CTX320 led to durable reductions of ANGPTL3 protein and lipoprotein(a) levels respectively in non-human primates after a single dose. Both were well-tolerated at clinically relevant dose levels. A clinical trial has been initiated for CTX310, while CTX320 is set to enter the clinic in the first half of 2024.
November 06, 2023 | 10:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crispr Therapeutics' announcement of positive preclinical data for its cardiovascular disease treatments CTX310 and CTX320 could potentially boost investor confidence. The initiation of clinical trials for CTX310 and the planned entry of CTX320 into the clinic in 2024 indicate progress in the company's pipeline.
Positive preclinical data generally boosts investor confidence as it indicates potential efficacy of the treatments. The initiation of clinical trials for CTX310 and the planned entry of CTX320 into the clinic in 2024 show progress in Crispr Therapeutics' pipeline, which could positively impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100